Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07086443 · ClinicalTrials.gov registry record · Phase 4

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy

A Phase 4 study of Diabetic Foot Ulcer and Diabetic Foot Ulcer (DFU), sponsored by Sequence LifeScience.

Recruiting
Registry status
Phase 4
Development phase
350
Enrollment target
1
Study location

NCT07086443: Recruiting Phase 4 study of Diabetic Foot Ulcer and Diabetic Foot Ulcer (DFU), sponsored by Sequence LifeScience.

NCT07086443 is a Phase 4 study of Diabetic Foot Ulcer and Diabetic Foot Ulcer (DFU) that is actively recruiting participants, run by Sequence LifeScience. The registered enrollment target is 350 participants, above the 250-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07086443, a Phase 4 study of Diabetic Foot Ulcer and Diabetic Foot Ulcer (DFU), is actively recruiting participants, sponsored by Sequence LifeScience.

RECRUITING
Registry status
Phase 4
Development phase
350 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks using a modified platform trial design.

Primary Outcome

To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks using a modified platform trial design.

Interventions

  • OTHER Activate™ Matrix
  • OTHER AmnioDefend™ FT Matrix
  • OTHER Palisade™ DM Matrix
  • OTHER Enclose™ TL Matrix
  • OTHER Sentry™ SL Matrix

Study Locations (1)

Pennsylvania

  • Serena Group- Monroeville - Monroeville

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2025-07-11
Est. Completion 2027-07
Phase Phase 4
Sequence LifeScience

2 total trials

What NCT07086443 shows while recruiting

NCT07086443 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 250-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (40% higher).

The record links to 7 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 5 interventions - of which Activate™ Matrix is the first listed.

NCT07086443 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07086443 about?

NCT07086443 is a clinical study titled "Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy". The goal of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers with multiple CAMPs plus SOC versus matched controls over 12 weeks using a modified platform trial design.

What is the current status of trial NCT07086443?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2025-07-11. Estimated completion is 2027-07.

What conditions does trial NCT07086443 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer, Diabetic Foot Ulcer (DFU), Ulcer, Ulcer Foot, DFU.

What interventions are being tested in trial NCT07086443?

The interventions under investigation include: Activate™ Matrix (OTHER), AmnioDefend™ FT Matrix (OTHER), Palisade™ DM Matrix (OTHER), Enclose™ TL Matrix (OTHER), Sentry™ SL Matrix (OTHER).

Who is sponsoring clinical trial NCT07086443?

This trial is sponsored by Sequence LifeScience, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07086443 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07086443's enrollment target sits among peer trials

350 7th of 67 higher than 60 of 67 other Diabetic Foot Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07086443, the US trial registry maintained by the National Library of Medicine. NCT07086443 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.